BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• Alimera Sciences to Present at the MicroCap Rodeo Winter Wonderland Best Ideas Virtual Investor Conference

  Alimera Sciences, Inc. today announces that Rick Eiswirth, Alimera’s President and Chief Executive Officer will present at the MicroCap Rodeo Winter Wonderland Best Ideas Virtual Investor Conference, which is being held virtually from February 8 – 11, 2022.

  February 4, 2022

   · 

  1 min read
• Drug Development

  Revolo Biotherapeutics Receives MHRA Approval for Two Phase 2 Clinical Trials of ‘1805 in Autoimmune Diseases in the United Kingdom

  Revolo Biotherapeutics today announced that it has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to commence two Phase 2 clinical trials to evaluate its immune-resetting drug candidate.

  February 4, 2022

   · 

  3 min read
• SomaLogic Provides 2022 Revenue Guidance in Conjunction with Analyst and Investor Meeting

  SomaLogic, Inc., a leader in AI-data driven proteomics technology, will host a virtual analyst and investor meeting today, February 4th , 2022, from 10:00 a.m. to approximately 1:00 p.m. Eastern Time.

  February 4, 2022

   · 

  4 min read
• Genetown

  Hemab Therapeutics Announces First Drug Candidate: HMB-001, a Novel Bispecific Antibody with Potential for Treatment of Rare Bleeding Disorders

  Preclinical data demonstrate HMB-001’s promise as a preventative treatment for patients with underserved bleeding disorders, including Glanzmann Thrombasthenia.

  February 4, 2022

   · 

  3 min read
• Deals

  OTR Acquisition Corp. Announces Confidential Submission of S-4 Registration Statement Related to Proposed Business Combination

  Investor Call Rescheduled to Tuesday, Feb. 8 at 8:30 a.m. EST to Discuss Combination between Comera Life Sciences, Inc. and OTR Acquisition Corp.

  February 4, 2022

   · 

  6 min read
• Business

  Amneal to Report Fourth Quarter and Full Year 2021 Results on March 2, 2022

  Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) announced today that the Company will release its fourth quarter and full year 2021 financial results on Wednesday, March 2, 2022, prior to market open.

  February 4, 2022

   · 

  1 min read
• Genetown

  Cedilla Therapeutics to Present at Upcoming Investor Conferences

  Cedilla Therapeutics today announced that Alexandra Glucksmann, Ph.D., President and Chief Executive Officer will present a corporate update at the following upcoming investor conferences in February.

  February 4, 2022

   · 

  1 min read
• Business

  eRAMx™, Exclusive Partnership with Cynergy Wellness, Inc. for Live Virtual Test Administration

  ABK Remote Drug Testing, Inc., owner of eRAMx™ Live Remote Drug Testing, and Cynergy Wellness, Inc. today announce an exclusive partnership to deliver virtual test administration and result interpretation to the workplace.

  February 4, 2022

   · 

  4 min read
• Cardiac Marker Analyzers Market: Rise in prevalence of cardiac diseases to drive the market

  Cardiac marker analyzer, also known as cardiac reader system, is an important tool to prevent misdiagnoses of cardiac conditions such as myocardial infarction.

  February 4, 2022

   · 

  6 min read
• Antiulcerant Drugs Market: Rising awareness about ulcer diseases to drive the market

  Antiulcerant drugs are a wide class of drugs used in treating ulcers of the stomach and intestine.

  February 4, 2022

   · 

  5 min read